Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Roberto Petrioli, Edoardo Francini, Anna Ida Fiaschi, Letizia Laera & Giandomenico Roviello. (2015) Targeted Therapies for Prostate Cancer. Cancer Investigation 33:7, pages 276-285.
Read now
Read now
Articles from other publishers (21)
Daniel A. González-Padilla & José Daniel Subiela. (2023) Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not. European Urology.
Crossref
Crossref
Jun Furumido, Nako Maishi, Aya Yanagawa‐Matsuda, Hiroshi Kikuchi, Ryuji Matsumoto, Takahiro Osawa, Takashige Abe, Yoshihiro Matsuno, Nobuo Shinohara, Yasuhiro Hida & Kyoko Hida. (2022) Stroma biglycan expression can be a prognostic factor in prostate cancers. International Journal of Urology 30:2, pages 147-154.
Crossref
Crossref
Xing-Hui Wang, Zhi-Qiang Wang, Zhen-Yu Mu, Li-Ping Zhu, Chong-Fu Zhong & Shanchun Guo. (2022) The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Medicine 101:31, pages e29715.
Crossref
Crossref
Giandomenico Roviello, Martina Catalano, Carlotta Ottanelli, Roberta Giorgione, Virginia Rossi, Elisabetta Gambale, Chiara Casadei, Ugo De Giorgi & Lorenzo Antonuzzo. (2022) Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice. Medical Oncology 39:10.
Crossref
Crossref
Zejie Mei, Tao Yang, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu, Yingyi Qin, Xi Chen, Chengdang Xu, Cuidong Bian, Xinan Wang, Chenyang Wang, Denglong Wu, Shengsong Huang & Zhenfei Li. (2022) Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell Reports Medicine 3:5, pages 100608.
Crossref
Crossref
Zemin Hou, Shengsong Huang & Zhenfei Li. (2021) Androgens in prostate cancer: A tale that never ends. Cancer Letters 516, pages 1-12.
Crossref
Crossref
Yushi Naito, Masashi Kato, Hideji Kawanishi, Yuri Yuguchi, Takuma Yuba, Tomohiro Ishikawa, Kyosuke Hattori, Akiyuki Yamamoto, Tomoyasu Sano, Yoshihisa Matsukawa, Toru Kimura, Toshinori Nishikimi, Ryohei Hattori, Toyonori Tsuzuki & Momokazu Gotoh. (2020) The clinical benefit of sequential therapy with androgen receptor axis‐targeted agents alone in patients with castration‐resistant prostate cancer: A propensity score‐matched comparison study. The Prostate 80:15, pages 1373-1380.
Crossref
Crossref
G. Roviello, M. R. Gatta Michelet, A. D’Angelo, S. Nobili & E. Mini. (2019) Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. Clinical and Translational Oncology 22:7, pages 1033-1039.
Crossref
Crossref
Giandomenico Roviello, Navid Sobhani, Silvia Paola Corona & Alberto D’Angelo. (2019) Corticosteroid switch after progression on abiraterone acetate plus prednisone. International Journal of Clinical Oncology 25:2, pages 240-246.
Crossref
Crossref
Doo Yong Chung, Dong Hyuk Kang, Jong Won Kim, Do Kyung Kim, Joo Yong Lee, Chang Hee Hong & Kang Su Cho. (2019) Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Cancers 12:1, pages 8.
Crossref
Crossref
Giandomenico Roviello, Silvia Paola Corona, Raffaele Conca, Roberto Petrioli, Pietro Rosellini, Alberto Bonetta & Michele Aieta. (2019) Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?. Medicine 98:26, pages e16249.
Crossref
Crossref
Hideaki Miyake, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Takayuki Sugiyama & Atsushi Otsuka. (2017) No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology 23:3, pages 576-583.
Crossref
Crossref
Hideaki Miyake, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Takayuki Sugiyama & Atsushi Otsuka. (2017) Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. Medical Oncology 34:12.
Crossref
Crossref
Hideaki Miyake, Takuto Hara, Seiichiro Ozono & Masato Fujisawa. (2017) Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 15:2, pages e217-e222.
Crossref
Crossref
Yundong He, Shihong Peng, Jinhua Wang, Huang Chen, Xiaonan Cong, Ang Chen, Meichun Hu, Min Qin, Haigang Wu, Shuman Gao, Liguo Wang, Xin Wang, Zhengfang Yi & Mingyao Liu. (2016) Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. Nature Communications 7:1.
Crossref
Crossref
Giandomenico Roviello, Maria Rosa Cappelletti, Laura Zanotti, Angela Gobbi, Chiara Senti, Alberto Bottini, Andrea Ravelli, Alberto Bonetta, Giovanni Paganini & Daniele Generali. (2016) Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer. Medicine 95:43, pages e4636.
Crossref
Crossref
Julia Hoefer, Mohammady Akbor, Florian Handle, Philipp Ofer, Martin Puhr, Walther Parson, Zoran Culig, Helmut Klocker & Isabel Heidegger. (2016) Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. Oncotarget 7:37, pages 59781-59794.
Crossref
Crossref
Mayura Nakano, Sunao Shoji, Taro Higure, Masayoshi Kawakami, Tetsuro Tomonaga, Toshiro Terachi & Toyoaki Uchida. (2016) Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer. Molecular and Clinical Oncology.
Crossref
Crossref
Giandomenico Roviello, Roberto Petrioli, Letizia Laera & Edoardo Francini. (2015) The third line of treatment for metastatic prostate cancer patients: Option or strategy?. Critical Reviews in Oncology/Hematology 95:3, pages 265-271.
Crossref
Crossref
Roberto Petrioli, Edoardo Francini, Letizia Laera, Anna Ida Fiaschi, Roberto Ponchietti & Giandomenico Roviello. (2015) Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. Cancer Chemotherapy and Pharmacology 76:3, pages 439-445.
Crossref
Crossref
R. Petrioli, G. Roviello, A. I. Fiaschi, L. Laera, Salvatora T. Miano, G. De Rubertis, G. Barbanti, V. Bianco, S. Brozzetti & E. Francini. (2015) Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. Medical Oncology 32:3.
Crossref
Crossref